Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience

BACKGROUND: The purpose of this paper is to report real-world data on the relative effectiveness of a biosimilar erythropoiesis-stimulating agent (ESA; Binocrit(®)), and other available ESAs for the treatment of chemotherapy-induced anemia. METHODS: Data were collected retrospectively from single ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez Garzotto, Analia, Heine, Oliver, Turner, Matthew, Rebollo Laserna, Francisco, Lorenz, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011805/
https://www.ncbi.nlm.nih.gov/pubmed/24855398
http://dx.doi.org/10.2147/JBM.S57887
_version_ 1782314848069091328
author Rodriguez Garzotto, Analia
Heine, Oliver
Turner, Matthew
Rebollo Laserna, Francisco
Lorenz, Andreas
author_facet Rodriguez Garzotto, Analia
Heine, Oliver
Turner, Matthew
Rebollo Laserna, Francisco
Lorenz, Andreas
author_sort Rodriguez Garzotto, Analia
collection PubMed
description BACKGROUND: The purpose of this paper is to report real-world data on the relative effectiveness of a biosimilar erythropoiesis-stimulating agent (ESA; Binocrit(®)), and other available ESAs for the treatment of chemotherapy-induced anemia. METHODS: Data were collected retrospectively from single centers in Spain (n=284) and Germany (n=145). Hemoglobin outcomes, transfusion requirements, and serious drug-related adverse events were assessed for each ESA. RESULTS: Hemoglobin outcomes and transfusion requirements were generally similar in the different ESA treatment groups assessed. No serious drug-related adverse events were recorded in any of the treatment groups. CONCLUSION: These data confirm the real-world effectiveness and safety of a biosimilar ESA (Binocrit(®)) for the treatment of cancer patients with chemotherapy-induced anemia.
format Online
Article
Text
id pubmed-4011805
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-40118052014-05-22 Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience Rodriguez Garzotto, Analia Heine, Oliver Turner, Matthew Rebollo Laserna, Francisco Lorenz, Andreas J Blood Med Original Research BACKGROUND: The purpose of this paper is to report real-world data on the relative effectiveness of a biosimilar erythropoiesis-stimulating agent (ESA; Binocrit(®)), and other available ESAs for the treatment of chemotherapy-induced anemia. METHODS: Data were collected retrospectively from single centers in Spain (n=284) and Germany (n=145). Hemoglobin outcomes, transfusion requirements, and serious drug-related adverse events were assessed for each ESA. RESULTS: Hemoglobin outcomes and transfusion requirements were generally similar in the different ESA treatment groups assessed. No serious drug-related adverse events were recorded in any of the treatment groups. CONCLUSION: These data confirm the real-world effectiveness and safety of a biosimilar ESA (Binocrit(®)) for the treatment of cancer patients with chemotherapy-induced anemia. Dove Medical Press 2014-04-28 /pmc/articles/PMC4011805/ /pubmed/24855398 http://dx.doi.org/10.2147/JBM.S57887 Text en © 2014 Rodriguez Garzotto et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Rodriguez Garzotto, Analia
Heine, Oliver
Turner, Matthew
Rebollo Laserna, Francisco
Lorenz, Andreas
Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience
title Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience
title_full Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience
title_fullStr Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience
title_full_unstemmed Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience
title_short Erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience
title_sort erythropoiesis-stimulating agents for the treatment of chemotherapy-induced anemia: comparisons from real-world clinical experience
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011805/
https://www.ncbi.nlm.nih.gov/pubmed/24855398
http://dx.doi.org/10.2147/JBM.S57887
work_keys_str_mv AT rodriguezgarzottoanalia erythropoiesisstimulatingagentsforthetreatmentofchemotherapyinducedanemiacomparisonsfromrealworldclinicalexperience
AT heineoliver erythropoiesisstimulatingagentsforthetreatmentofchemotherapyinducedanemiacomparisonsfromrealworldclinicalexperience
AT turnermatthew erythropoiesisstimulatingagentsforthetreatmentofchemotherapyinducedanemiacomparisonsfromrealworldclinicalexperience
AT rebollolasernafrancisco erythropoiesisstimulatingagentsforthetreatmentofchemotherapyinducedanemiacomparisonsfromrealworldclinicalexperience
AT lorenzandreas erythropoiesisstimulatingagentsforthetreatmentofchemotherapyinducedanemiacomparisonsfromrealworldclinicalexperience

Ejemplares similares